Sodium Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Sodium Chloride: From Established Clinical Use to Breast Fibrocystic Disease
One-Sentence Summary
Sodium chloride is a widely used isotonic agent, but this evidence pack contains no documented original indication or marketing authorisation data for it in this jurisdiction. The TxGNN model predicts it may be effective for Breast Fibrocystic Disease, but this is supported by only 1 clinical trial (a diagnostic imaging study, not a treatment trial) and 7 publications (mostly basic-science biochemistry of cyst fluid). Evidence quality is very low and does not currently support this signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no licences or indication text on file) |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for sodium chloride in this evidence pack, and no original indication is recorded either, so a direct mechanistic bridge between an established use and the predicted indication cannot be constructed from the data provided.
The evidence pack’s own rationale for this prediction is explicit that no mechanistic link exists: sodium chloride is an isotonic plasma component, and there is no evidence that it has a therapeutic effect on fibrocystic breast disease. The single associated clinical trial (NCT02887937) is a diagnostic contrast-enhanced ultrasound study evaluating whether biopsy is needed for cystic breast masses — it does not test sodium chloride as a treatment. The literature is dominated by basic-science biochemical analyses of breast cyst fluid composition (sodium/potassium/chloride ratios, protein content) rather than interventional treatment studies.
Taken together, this is a model-generated signal (high TxGNN similarity score) without corroborating mechanistic, preclinical, or clinical treatment evidence. It should be treated as hypothesis-generating only.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02887937 | N/A | Completed | 135 | Evaluated contrast-enhanced ultrasound to assess whether cystic breast masses need biopsy. This is a diagnostic imaging study — it did not test sodium chloride as a treatment (relevance grade: C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2015669 | 1991 | Basic Science | Clinical Chemistry | Protein GCDFP-70 in breast cyst fluid identified as albumin; used to classify cyst types (not a treatment study) |
| 2140797 | 1990 | Basic Science | Eur J Surg Oncol | Breast cyst fluids classified by Na⁺/K⁺ ratio, chloride, glucose, pH and hormone content |
| 9375824 | 1997 | Basic Science | Nephron | Compared amino acid/electrolyte osmotic contributions in kidney cyst fluid vs breast cyst fluid |
| 10797312 | 2000 | Basic Science | Journal of Cellular Physiology | Intracellular pH regulation compared in non-malignant vs malignant breast cell lines |
| 3369685 | 1988 | Basic Science | Analytical Biochemistry | Collagen fractionation technique using alkaline potassium chloride in breast tissue samples |
| 3232934 | 1988 | Case Series | Annals of Plastic Surgery | Nine-year experience with saline-inflatable prostheses for breast reconstruction (device use, not disease treatment) |
| 23073330 | 2012 | Case Report | American Journal of Surgical Pathology | Rare NK/T-cell lymphoma reported in association with a saline breast implant |
UK Market Information
No UK marketing authorisation records are available in this evidence pack. Market status is recorded as Not marketed, with 0 licences on file.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: this evidence pack flags MHRA/SmPC warnings and contraindications for sodium chloride as an outstanding, blocking data gap — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (breast fibrocystic disease) has no supporting mechanistic rationale, no treatment-focused clinical trials, and only basic-science literature on cyst fluid biochemistry. Combined with the absence of original indication, MOA, and UK regulatory/safety data, the evidence base is insufficient to justify progression at this time. (The other nine predicted indications in this evidence pack show similarly weak or absent evidence, mostly also scored Hold/L5.)
To proceed, the following is needed:
- MHRA-approved SmPC data: key warnings, contraindications and drug interactions (currently a blocking gap)
- Confirmed mechanism of action data (e.g. via DrugBank)
- Documented original/established indication(s) for sodium chloride in this jurisdiction
- At least one interventional (not diagnostic or biochemical) study directly testing sodium chloride in breast fibrocystic disease before any further evaluation stage is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.